(PR-inside.com) - Cell Signaling Technology, Inc. (CST) announced today the renewal of a research agreement with Ortho-Biotech Oncology Research and Development (ORD), a Division of Janssen Pharmaceutica, N.V., under which CST will employ its patented PhosphoScan(R) and PTMScan(TM) technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors. PhosphoScan and PTMScan proteomics are patented strategies for extensive profiling and discovery of phosphorylation and other post-translational modifications (PTM) in cells and tissues. CST's PTMScan platform provides unbiased and quantitative analysis of phosphorylation, acetylation and ubiquitination, and most significantly, changes in these post-translational modification ..
More...
More...